Here's Where Wall Street Analysts See Eli Lilly's Share Price Going

Eli Lilly (NYSE: LLY) has had an impressive run over the past few years. The stock is up 410% over the last five years and 58% over the past 52 weeks. Its performance this year, however, has been a bit more modest, up just 10.1%. So, it's underperforming the broader market, as measured by the S&P 500 (SNPINDEX: ^GSPC), which gained around 12.5% so far in 2026.

I think the deceleration in the stock's climb this year is probably due to its run-up over the past few years, which has made it expensive. Lilly currently trades at about 40 times trailing earnings.

Image source: Getty Images.

But remember, Eli Lilly makes the world's best-selling drug. In the third quarter of 2025, the company's tirzepatide, a GLP-1 dual receptor agonist, overtook Merck's blockbuster cancer drug Keytruda as the top seller worldwide. Tirzepatide is sold as Mounjaro to treat type 2 diabetes and Zepbound for weight loss.

And the market for GLP-1 drugs is projected to soar. Morgan Stanley sees it hitting $190 billion by 2045, more than double the 2025 level. The investment bank recently increased its forecast by $40 billion due to the launch of oral therapies and the expansion of Medicare coverage in the U.S.

Wall Street is moderately bullish on Eli Lilly

So where does the stock go from here? Well, I checked the latest data on price targets for Lilly shares, which are Wall Street analysts' official predictions of where the stock will be in 12 to 18 months, based on historical and projected earnings. All in all, analysts covering the stock are bullish, though not overly so.

The average price target for Lilly is $1,325, which is about 11% above the current price of $1,193. And of the 30 major analysts that cover Eli Lilly, 25 recommend a "buy" or "strong buy." Citigroup is the most bullish on the drugmaker, with a "buy" recommendation and a price target of $1,600. HSBC is the most bearish, with a target of $940 and a rating of "reduce."

Some of these analysts are probably concerned that Lilly's current dominance in the GLP-1 market won't last. Lilly's main competitor in the GLP-1 space, Novo Nordisk (NYSE: NVO), has developed its own oral GLP-1 weight loss drug called Wegovy. And other companies are looking to do the same. But Lilly's tirzepatide has patents that extend into the late 2030s, and the company has several follow-on patents for delivery devices, formulations, and treatment methods.

So yes, Lilly is an expensive stock. But the outlook for the GLP-1 market, coupled with Lilly's strong patents, makes me a bit more bullish on the stock than the average analyst.

Citigroup is an advertising partner of Motley Fool Money. HSBC Holdings is an advertising partner of Motley Fool Money. Matthew Benjamin has positions in Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool recommends HSBC Holdings. The Motley Fool has a disclosure policy.